Madrigal Pharmaceuticals presents new data on Rezdiffra

Madrigal Pharmaceuticals (MDGL) announced positive two-year data from the open-label compensated MASH cirrhosis arm of the Phase 3 MAESTRO-NAFLD-1 trial, evaluating the use of Rezdiffra in an advanced, difficult-to-treat patient population with no approved therapies. The F4c data, and multiple additional Rezdiffra abstracts from the Phase 3 MAESTRO program, were presented at the American Association for the Study of Liver Diseases, AASLD, The Liver Meeting, taking place from November 7-11, 2025, in Washington, D.C. Key points: Rezdiffra treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis; Rezdiffra also improved disease-specific quality of life measures in patients with and without cirrhosis, with sustained effect through two years of treatment; New analysis examining effects of Rezdiffra treatment interruption underscores the need for sustained therapy to prevent disease progression